Factors related to tumor response rate from TCGA three omics data-variants, expression, methylation

扫码查看

原文链接

NETL
NSTL
Taylor & Francis

外文摘要：The Cancer Genome Atlas (TCGA) and its patient-derived multi-omics datasets have been the backbone of cancer research, and with novel approaches, it continues to shed new insight into the disease. In this study, we delved into a method of multi-omics integration of patient datasets and the association of biological pathways related to the disease. First, across thirty-three types of cancer present in TCGA, we merged genomic mutations and drug response datasets and filtered for the viable variant-drug response combinations available in TCGA, containing more than three samples for each drug response label with RNA sequencing (RNA-seq) and genomic methylation data available for each patient. We identified two distinct combinations in TCGA, one being pancreatic adenocar-cinoma patients with/without rs121913529 variant in KRAS gene treated with gemcitabine, and the other low-grade glioma with/ without rs121913500 variant in IDH1 gene administered with temozolomide. In these two groups, different patterns of gene expression were observed in the pathways often associated with cancer progression, such as mTOR and PDGF between the patients with complete response and progressive disease. Our result will provide yet another example of the relevance of these biological pathways in cancer drug response and a way for multi-omics integration in cancer datasets.

外文关键词：

Cancervariantstumor response rategene expressionDNA methylation

作者：

Hyung-Min Ahn、Insu Park、Chang Geun Kim、Young Kyung Ko、Jeong-An Gim

展开 >

作者单位：

Center for Lung Cancer, National Cancer Center Hospital, Goyang, South Korea||BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul, South Korea

BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul, South Korea||Department of Laboratory Medicine, Korea University Guro Hospital, Seoul, South Korea

Center for Lung Cancer, National Cancer Center Hospital, Goyang, South Korea||Department of Thoracic and Cardiovascular Surgery, Korea University Guro Hospital, Seoul, South Korea

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea

Department of Medical Science, Soonchunhyang University, Asan, South Korea

展开 >

出版年：

2024

DOI：

10.1080/26896583.2024.2319010

Journal of Environmental Science and Health, Part C. Toxicology and Carcinogenesis

ISSN：2689-6583

年,卷(期)：2024.42(1/4)

参考文献量31